Business Wire

Inaugural Dealroom and NATO Innovation Fund Report Reveals Record-Breaking Investing in Startups in European Defence, Security, and Resilience Sector

12.2.2025 06:05:00 CET | Business Wire | Press release

Share

The Defence, Security and Resilience sector reached $5.2 billion in 2024, an all-time high.The sector has outperformed the overall VC (Venture Capital) sector, marking a 30 percent increase over the past two years.Munich has emerged as the top VC hub in Europe for this segment in 2024.To help support the integration of the growing number of emerging technologies in this segment by governments and businesses, the NATO Innovation Fund is announcing the hiring of John Ridge as Chief Adoption Officer.

Dealroom.co and the NATO Innovation Fund - a €1 billion VC (Venture Capital) backed by 24 NATO countries – published today their inaugural report on the state of Defence, Security and Resilience in Europe, revealing a record-breaking year for investing in this segment. This highlights the critical role that the sector is playing in maintaining Europe’s technological edge and sovereignty amidst a broader market downturn.

Key findings from the report reveal:

  1. VC funding in the DSR (defence, security and resilience) sector is at an all-time high, reaching $5.2 billion in 2024. Overall, investing is up nearly 5x in the last six years. With companies in early and breakout stages driving this growth, a strong pipeline to scaling is expected in the coming years.
  2. DSR investing has increased by 30 percent over the past two years - the strongest growth among all VC deep tech segments. The segment has significantly outperformed the overall VC market, which witnessed a 45 percent decline in the same period of time.
  3. Defence startups have been leading in the segment’s growth. Companies developing technologies for Awareness, Understanding, and Decision Making – this includes technologies that help track risks and threats to enable faster and better decisions - have seen VC funding soar to a record $1 billion in 2024, up 4x since 2020 and nearly 2x since last year.

“Appetite for defence, security and resilience startup investment is unrecognisable in Europe from just a few years ago,” said Yoram Wijngaarde, Founder and CEO of Dealroom. “While overall VC funding contracted by 45 percent in the past two years, defence and security tech investment has grown by 30 percent to reach $5.2 billion last year. It follows an ongoing trend of putting capital and innovation to work on Europe's core strategic needs, via deep technologies. Despite recent growth, defence, security and resilience tech remains a relatively nascent sector, but the data shows an active pipeline of early-stage companies looking to change that.”

“Europe has the talent and resources to become a global leader in technologies for Defence, Security and Resilience,” said Kelly Chen, Partner at the NATO Innovation Fund. “We're excited to see this sector drive the momentum in Deep Tech this year and are committed to investing in technologies that can secure the region's future.”

Germany and the UK are emerging as regional leaders

  1. Munich emerged as Europe's top hub for DSR investment, followed by Oxford in the UK and Paris in France.
  2. The UK has attracted the most VC funding in DSR since 2019. However, Germany claimed the top spot in 2024, followed by the UK and France.
  3. Since 2019, Switzerland and the Netherlands have invested 7 percent of their total national VC funding in DSR companies. That marks the largest share of national funding invested in this segment.
  4. The UK boasts five of the top ten DSR hubs (Oxford, London, Cambridge, Bristol, and Reading), while Germany follows with two (Munich, Berlin).

“The Munich metropolitan region is becoming a hub for next-generation defence companies, offering industrial and testing facilities, top talent, a regional industrial supply chain, and connections to German defence customers and traditional primes,” said Marc Wietfeld, Co-Founder & CEO, ARX. “With ARX, we aim to bridge the gap between emerging players, new defence primes, and established contractors.”

Laying the foundation for technological adoption in Europe

The report’s findings indicate that Europe's emerging tech landscape is undergoing a significant transformation in the defence, security and resilience space, driven by geopolitical developments and a growing demand for emerging technologies that can secure the region’s future. In a recently released paper, the NATO Innovation Fund called for the creation of adoption pathways for the integration of emerging technologies in the defence and security infrastructure of European ministries of defence.

To help support with the creation of these pathways, as well as in order to connect large European businesses with startup founders who have developed deep tech solutions that can help the region maintain its technological edge for generations to come, the NATO Innovation Fund is announcing today the hiring of John Ridge as Chief Adoption Officer.

John joins the NATO Innovation Fund after spending nearly three decades in the UK’s Armed Forces and Civil Service. He is also a Commissioner on the Atlantic Council’s current Commission on Software-Defined Warfare.

“I am extremely proud to be joining the NATO Innovation Fund to help get the cutting-edge capabilities of our portfolio companies into the hands of users across the Alliance,” said John Ridge, Chief Adoption Officer, NATO Innovation Fund. “I look forward to working hand-in-hand with NATO, national governments and defence industry leaders to help the technologies that we are backing make a difference to the Alliance's ability to deter further aggression by our adversaries.”

About the NATO Innovation Fund:

The NATO Innovation Fund is a €1 billion venture capital fund, backed by 24 NATO Allies, that invests in deep tech to address challenges in defence, security, and resilience. The fund invests independently, with 24 nations supporting its portfolio’s success and helping provide deep tech entrepreneurs with access to both commercial and government markets.

Participating NATO Allies are: Belgium; Bulgaria; Czechia; Denmark; Estonia; Finland; Germany; Greece; Hungary; Iceland; Italy; Latvia; Lithuania; Luxembourg; Netherlands; Norway; Poland; Portugal; Romania; Slovakia; Spain; Sweden; Türkiye; United Kingdom.

About Dealroom.co:

Dealroom.co is a global intelligence platform for discovering and tracking the most promising companies, technologies and ecosystems. Clients include many of the world’s foremost organizations such as Sequoia, Accel, Index Ventures, NATO Innovation Fund, Nato Diana, ESA, McKinsey, BCG, Deloitte, Google, AWS, Microsoft, Stripe.

Dealroom partners closely with local tech ecosystem development agencies and enablers, to create a comprehensive multi-dimensional blueprint of the tech ecosystem, including capital, talent, innovation, entrepreneurship and overall economic dynamism.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211886043/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye